# Myo-Inositol - Clinical Longevity Review & Consensus Audit

> **Consensus Verdict**: Myo-Inositol is an essential intracellular carbocyclic sugar serving as the structural precursor for inositolphosphoglycan (IPG) second messengers that couple insulin receptor activation to downstream GLUT4 glucose transporter translocation. Systematic meta-analyses and double-blind clinical trials prove that myo-inositol supplementation reduces HOMA-IR by 36%, decreases fasting plasma insulin by 28%, drops pathological elevated testosterone by 65% in women with PCOS, and reverses metabolic syndrome criteria in postmenopausal women, producing statistically significant reductions in triglycerides (-20%) and increases in cardioprotective HDL cholesterol (+18%).

## 1. Executive Summary & Scores
- **Longevity Evidence Score**: **93/100**
- **Evidence Quality Tier**: **silver**
- **Human Clinical Evidence Strength**: 95/100
- **Primary Longevity Classification**: supplements
- **Safety Margin Score**: 96/100 (Higher is safer)
- **Time Burden**: ~1 minutes/day
- **Estimated Monthly Cost**: inexpensive
- **Adherence Friction**: 1/10 (Lower is easier to sustain)

---

## 2. Biological Mechanisms of Action
Precursor to PIP3; acts as a second messenger in insulin and neurotransmitter (serotonin/dopamine) signal transduction pathways.

---

## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars)
- **Heart Health & Endothelial Function**: **84/100** [Rank #19 of 133 in Heart] - Effect: High (-20.4% Serum Triglycerides, +18.2% Protective HDL-C in Metabolic Syndrome RCT)
    - Mechanism: Reverses hepatic de novo lipogenesis driven by compensatory hyperinsulinemia, significantly improving systemic lipid panels and vascular endothelial compliance.
- **Brain Longevity & Neuroprotection**: **80/100** [Rank #40 of 141 in Brain] - Effect: High (Phosphoinositide second messenger regulation of serotonin 5-HT2 and dopamine D2 signaling)
    - Mechanism: Restores membrane phosphatidylinositol pools in the central nervous system, re-sensitizing monoaminergic receptors and mitigating panic and obsessive-compulsive behaviors.
- **Metabolic Flexibility & Glycemic Control**: **96/100** [Rank #1 of 129 in Metabolic] - Effect: Very High (-36% HOMA-IR, -28% Fasting Insulin, Normalizes OGTT Curve in RCTs)
    - Mechanism: Acts as the essential biological precursor for inositolphosphoglycan (IPG) second messengers that directly mediate post-receptor insulin signaling, driving sarcolemmal GLUT4 translocation and glycogen synthesis.
- **Cancer Defense & DNA Repair**: **60/100** [Rank #33 of 120 in Cancer Defense] - Effect: Moderate (Preclinical modulation of phosphoinositide 3-kinase oncogenic survival signals)
    - Mechanism: Competes with hyperactive PI3K/Akt signaling cascades, inducing cell-cycle arrest in aberrant epithelial cells.
- **Endocrine & Anabolic Balance**: **82/100** [Rank #9 of 120 in Endocrine] - Effect: High (-65% Elevated Serum Testosterone in Hyperandrogenic Women, Normalizes Endocrine Axis)
    - Mechanism: Corrects ovarian theca cell insulin resistance, attenuating pathological CYP17A1-driven androgen hypersecretion and restoring normal pituitary gonadotropin feedback.
- **Chronic Inflammation Reduction**: **78/100** [Rank #38 of 126 in Inflammation] - Effect: Moderate-High (Suppresses metabolic endotoxemia and adipocyte cytokine secretion)
    - Mechanism: Reduces visceral adipocyte lipolysis and downregulates proinflammatory cytokine release secondary to corrected insulin sensitivity.
- **Bone Density & Connective Matrix**: **55/100** [Rank #69 of 142 in Bone Matrix] - Effect: Mild-Moderate (Supports osteoblast differentiation via IP3 intracellular calcium pulses)
    - Mechanism: Regulates intracellular calcium release channels required for osteoblastic gene expression and bone matrix mineralization.
- **Cellular Longevity & Autophagy**: **75/100** [Rank #90 of 131 in Cellular] - Effect: Moderate (Structural constituent of membrane phosphatidylinositol and intracellular IP3 calcium release)
    - Mechanism: Serves as an indispensable structural building block for eukaryotic cellular membranes and secondary signal transduction cascades.

---

## 4. Practical Protocol & Administration Guidelines
- **Standard Clinical Dosage**: 1-2g for sleep, up to 4g for metabolism
- **Recommended Timing**: 30m before bed
- **Administration Type**: supplement
- **Recommended Biomarkers to Monitor**: satiety, mood, metabolic_health, energy, bone_density, heart_health

---

## 5. Safety, Contraindications & Drug Interactions
- **Contraindications**: Known severe hypersensitivity to inositol formulations
- **Safety Profile**: low_risk - Very well tolerated; mild gastrointestinal fullness or loose stools only at supratherapeutic doses exceeding 12 g/day

---

## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs
1. **Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study** [PMID: 20933215]
   - Link: https://pubmed.ncbi.nlm.nih.gov/20933215/
2. **Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials** [PMID: 28293997]
   - Link: https://pubmed.ncbi.nlm.nih.gov/28293997/
3. **Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial** [PMID: 19499845]
   - Link: https://pubmed.ncbi.nlm.nih.gov/19499845/
4. **Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with polycystic ovary syndrome** [PMID: 18074942]
   - Link: https://pubmed.ncbi.nlm.nih.gov/18074942/

---

## 7. Canonical Citation & Web Verification
- **Official Web Review**: [Myo-Inositol on LongevityReviews](https://longevityreviews.org/modalities/myo-inositol)
- **Last Evidence Calibration**: 2026-09-09
- **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.